22157.jpg
Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024
March 15, 2024 05:28 ET | Research and Markets
Dublin, March 15, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global acute...
22157.jpg
Respiratory Syncytial Virus Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F
March 04, 2024 10:06 ET | Research and Markets
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
February 27, 2024 15:52 ET | BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
22157.jpg
Procalcitonin Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
December 20, 2023 08:53 ET | Research and Markets
Dublin, Dec. 20, 2023 (GLOBE NEWSWIRE) -- The "Procalcitonin Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033" report has been added to ResearchAndMarkets.com's...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
October 16, 2023 14:40 ET | BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
ContraFect_LOGO_Web.jpg
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
October 16, 2023 07:30 ET | ContraFect Corporation
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Global Antimicrobial Susceptibility Testing Market
Global Antimicrobial Susceptibility Testing Market 2023-2030: Unveiling Treatment Efficacy - Antimicrobial Susceptibility Testing Market Soars with Focus on Personalized Medicine
September 08, 2023 06:28 ET | Research and Markets
Dublin, Sept. 08, 2023 (GLOBE NEWSWIRE) -- The "Antimicrobial Susceptibility Testing Market Size, Share & Trends Analysis Report By Product, By Technique, By Application, By End-use, By Region,...
Global Market for Pneumonia Testing
Pneumonia Testing Industry Landscape 2023-2030: U.S. and China Leading the Way
July 27, 2023 07:18 ET | Research and Markets
Dublin, July 27, 2023 (GLOBE NEWSWIRE) -- The "Pneumonia Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market analysis for...
Global Mycoplasma Testing Market
Mycoplasma Testing Global Market to 2030: Rising Cell Culture Contamination Drives Growth
July 06, 2023 06:48 ET | Research and Markets
Dublin, July 06, 2023 (GLOBE NEWSWIRE) -- The "Mycoplasma Testing Market Size, Share & Trends Analysis By Product (Instruments, Kits & Reagents), By Technology (PCR, ELISA, Direct Assay,...
22157.jpg
$43.1 Billion Point-of-Care Diagnostics Markets by Platform, Application, Sample Type, and End User - Global Forecast to 2030
June 01, 2023 09:23 ET | Research and Markets
Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Point-of-Care Diagnostics Market by Platform (LFA, Molecular), Application (TB, Pneumonia, Salmonellosis, Hepatitis, HIV, COVID-19, Pregnancy, Blood...